research Introductory Chapter: Alopecia Management – An Update
Some types of hair loss can be reversed, others are permanent, and treatments vary by type.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Systemic immunotherapies
Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.
research 63-Year-Old Female with Diffuse Thinning of the Hair
Androgenetic alopecia, a common hair loss condition, can be treated with topical minoxidil, oral finasteride, or oral spironolactone, and new treatments like platelet-rich plasma, low-level laser therapy, and janus-kinase inhibitors are being explored.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
Combination therapy effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Safety concerns when using novel medications to treat alopecia
Consider benefits and risks of new alopecia treatments for safety.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Management of folliculitis decalvans: The EADV task force on hair diseases position statement
Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.
research Pharmacological Treatment of Alopecia
Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
research Autoinmune Alopecia/Alopecia Areata
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
research A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization of severity and associated treatment utilization
More effective treatments are needed for severe alopecia areata.
research Assessment and treatment of adolescent hair loss
Early, tailored assessment and treatment are crucial for adolescent hair loss, with promising new diagnostic and treatment options.
research Revisión y avances en tricología
Recent advancements in hair loss treatments include new therapies and insights for different types of alopecia.
research Alopecia – New building blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Experience in treating multifocal alopecia areata in a child with Jak kinase inhibitors
JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
Tofacitinib may be safe and effective for treating certain skin conditions in children.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Two Birds that Exclude Each Other: The Renbök Phenomenon
Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research New Treatment Strategies in Management of Alopecia Areata: Review Article
New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.